Daniel Kremens
Neurology · Philadelphia, PANPI 1063433696
Payments from drug & device makers
Across 1,390 payments — averaging $1334.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$386K
- MDD US Operations, LLC$354K
- Teva Pharmaceuticals USA, Inc.$318K
- Acadia Pharmaceuticals Inc$264K
- Kyowa Kirin, Inc.$128K
- Acorda Therapeutics, Inc$117K
- plus $287K from 13 others
Across 2 payments — averaging $2532.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- H. Lundbeck A S$5K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 282 | $385,608 |
| MDD US Operations, LLC | 364 | $354,457 |
| Teva Pharmaceuticals USA, Inc. | 153 | $318,459 |
| Acadia Pharmaceuticals Inc | 200 | $263,687 |
| Kyowa Kirin, Inc. | 84 | $128,253 |
| Acorda Therapeutics, Inc | 84 | $117,443 |
| Amneal Pharmaceuticals LLC | 75 | $115,522 |
| AbbVie(2 entities) | 52 | $53,590 |
| Adamas Pharmaceuticals, Inc. | 25 | $46,680 |
| Merz Pharmaceuticals, LLC | 37 | $38,566 |
| Sunovion Pharmaceuticals Inc. | 13 | $15,153 |
| Lundbeck LLC | 6 | $8,094 |
| Tanabe Pharma America, Inc. | 6 | $5,041 |
| Avion Pharmaceuticals | 1 | $1,620 |
| H. Lundbeck A S | 2 | $1,534 |
| Biogen | 1 | $1,229 |
| Merz North America, Inc. | 3 | $148 |
| Supernus Pharmaceuticals, Inc. | 1 | $141 |
| Cala Health, Inc. | 1 | $24 |
How this compares
$1,855,248 in reported general payments places this provider in the 95th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Philadelphia
- Amit Bar-OrPhiladelphia$7.7M
- Thomas LeistPhiladelphia$5.8M
- Lauren ElmanPhiladelphia$3.3M
- David IrwinPhiladelphia$2.5M
- Frances JensenPhiladelphia$1.8M
- Andres Deik Acosta MadiedoPhiladelphia$1.8M
- Michael SperlingPhiladelphia$1.7M
- Sanjeev VaishnaviPhiladelphia$1.6M
- Andrew SiderowfPhiladelphia$1.4M
- Sami KhellaPhiladelphia$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.